Document:

Portions of this document have been redacted
pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under
the Securities Exchange Act of 1934, as amended. Redacted portions are indicated with the notation “*”.

 

SERVICES
AGREEMENT

 

This Services Agreement
(“Agreement”) is entered into as of the 8th day of October 2013 (“Effective Date”)
between Novartis Pharma AG located at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”) and Enumeral
Biomedical Corporation (a Delaware Company), located at 1450 Broadway 24th floor, New York, NY, 10018 (“Enumeral”),
each individually a “Party” or collectively “Parties” to this Agreement.

 

WHEREAS Enumeral
has proprietary technology and special expertise and a longstanding experience in the field of microwell devices for the immunological
and genetic analyses of single cells.

 

WHEREAS Novartis
wishes to retain the services of Enumeral in the field of microwell systems to evaluate the applicability of the technology for
the ex-vivo assessment of * from human samples *.

 

NOW THEREFORE,
the Parties agree as follows:

 

		1.	THE SERVICES

 

		1.1	Enumeral agrees to perform the services as described in Annex A attached hereto (the “Services”).

 

		1.2	Enumeral shall not subcontract the Services.

 

		1.3	Enumeral warrants that it shall provide the Services in accordance with the terms of this Agreement.

 

		1.4	Service Provider further warrants that it will provide the Services in a timely and professional
manner, in conformance with that level of care and skill ordinarily exercised by other professionals in similar circumstances;
and in compliance with all applicable laws and regulations.

 

		1.5	The Parties shall regularly communicate about all relevant matters with regard to the Services.
Enumeral shall promptly inform Novartis about any unforeseen results, problems, difficulties, delays, etc. with regard to the Services.
In case of a delay in the execution and/or performance of the Services, the Parties shall discuss the reasons for any such issues
and reasonable corporate to arrive at a solution. Without waiving any rights hereunder, Novartis agrees to review the timelines
in case of a delay by Enumeral in order to agree on revised timelines.

 

		1.6	At the conclusion of the Services, Enumeral will provide to Novartis the Novartis’ Results
(as defined in Section 4.3) generated during the performance of the Services in formats as outlined in Annex A. If results of Services
are transferred from Enumeral to Novartis by email, a secure email system as suggested by Novartis shall be used.

 

		1.7	Enumeral shall grant Novartis access to any data generated during the performance of the Services,
including without limitation electronic raw data and data contained in laboratory notebooks Upon Novartis’ request Enumeral
will provide Novartis with copies of data. Novartis will reimburse Enumeral for reasonable costs directly related to providing
Novartis with the requested copies.

 

		1.8	Enumeral will apply its proprietary technologies and materials as defined in Annex A (“Enumeral
Technology“) in the performance of the Services. Enumeral represents that it owns or has the right to use all rights
to the Intellectual Property which it shall use to perform the Services pursuant to this Agreement.

 

		1.9	Novartis shall provide to Enumeral on an ongoing basis during the term of this Agreement such information
and data as Enumeral reasonably requests for the performance of the Services.

 

    	Services Agreement Enumeral / Novartis	Page 1 of 12

    	 

    

 

Portions of this document have been redacted
pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under
the Securities Exchange Act of 1934, as amended. Redacted portions are indicated with the notation “*”.

 

		1.10	Novartis will provide to Enumeral biological and/or chemical materials (“Novartis Materials”)
as defined in Annex A for the performance of the Services and shall provide to Enumeral information related to such materials as
reasonably required by Enumeral in order to perform the Services. Enumeral shall use Novartis Materials only for the purpose of
performing the Services in accordance with this Agreement. Novartis shall provide Enumeral with instructions about how to handle
remaining Novartis Materials after completion of the Services prior to the conclusion of the Project. Enumeral shall comply with
Novartis’ instructions to either (i) destroy any Novartis Material at Enumeral’s costs; or (ii) transfer Novartis Materials
in accordance with Novartis’ instructions to Novartis, its Affiliates and/or a third party as indicated by Novartis in writing.
Costs related to the shipment of Novartis Materials shall be borne by Novartis.

 

		2.	PAYMENT TERMS

 

		2.1	In consideration of the performance of the Services by Enumeral, Novartis agrees to pay Enumeral
in accordance with the payment schedule set forth in Annex A.

 

		2.2	Upon completion of the Services as defined in the payment schedule in Annex A, Enumeral shall send
an invoice to Novartis Pharma AG, Zentraler Faktureneingang, Lichtstrasse 35, 4002 Basel, Switzerland with a copy to *.
The invoice must contain: (i) Enumeral name and address; (ii) the Services to which the invoice relates, the name of Novartis’
project leader (iii) the purchase order number; (iii) the amount invoiced; (iv) Enumeral’s VAT number, if applicable; and
(v) Enumeral’s account information. Except as specified in this Agreement, Enumeral will receive no other payments or reimbursements
from Novartis for or in connection with the Services.

 

		2.3	Payment will be made by Novartis within sixty (60) days from the date of receipt of the invoice,
to the bank account specified by Enumeral in accordance with Section 2.2.

 

		3.	CONFIDENTIALITY

 

		3.1	Enumeral undertakes to treat all scientific, technical, commercial and/or other information, data,
documents, results, etc., in whatever medium provided, which were (i) provided by or on behalf of Novartis or (ii) otherwise obtained
or developed in connection with the performance of Services under this Agreement, including but not limited to the Novartis Results,
(“Novartis Information”) as confidential, except for Novartis Information which Enumeral is able to demonstrate:

 

		(a)	was already in the possession of Enumeral at the time it was acquired from Novartis;

 

		(b)	is already generally available to the public, or subsequently becomes so available without default
on the part of Enumeral;

 

		(c)	is received by Enumeral from a third party who did not acquire it directly or indirectly from Novartis
in confidence; or

 

		(d)	is developed by Enumeral, independently from the Novartis Information disclosed;

 

For the sake
of clarity, information incorporated in the Enumeral Technology, Enumeral Background IP and Enumeral Improvements, shall not be
considered Novartis Information.

 

		3.2	Nothing in Section 3 shall prevent the disclosure of those parts of the Novartis Information which
are required to be disclosed by law or court order; provided however that if Enumeral is so required to disclose any such Novartis
Information, it shall provide Novartis prompt written notice of such requirement so that Novartis may seek a protective order or
other appropriate remedy to prevent or limit such disclosure.

 

    	Services Agreement Enumeral / Novartis	Page 2 of 12

    	 

    

 

Portions of this document have been redacted
pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under
the Securities Exchange Act of 1934, as amended. Redacted portions are indicated with the notation “*”.

 

		3.3	Enumeral represents and warrants that the Novartis Information will be used exclusively for the
purposes of this Agreement.

 

		3.4	After termination or expiry of this Agreement, Enumeral will upon Novartis written request return
to Novartis or, at Novartis’ option, will destroy any documents, reports and data provided by Novartis, documents, reports
and data containing Novartis Information, as well as all copies of and extracts from such documents, reports and data. Nevertheless
Enumeral may retain one (1) copy for the sole purpose of compliance with Enumeral’s legal obligations under applicable law.
Enumeral’s obligation under this Section 3.4 relate to any documents, reports and data in whatever medium provided.

 

		3.5	In case there is no confidentiality agreement in place between the Parties relating to the negotiations
of this Agreement, Enumeral represents and warrants that Novartis Information received from and/or on behalf of Novartis in the
course of the negotiations of this Agreement have been and will be treated in accordance with the confidentiality obligations as
set forth in this Section 3.

 

		4.	OwnerSHIP And INTELLECTUAL PROPERTY

 

		4.1	All tangible and intangible materials, data, results, information, documents, and reports, including
but not limited to Novartis Materials, provided to Enumeral by and/or on behalf of Novartis in connection with this Agreement,
in any form whatsoever, and any rights therein which were owned by or licensed to Novartis prior to being provided to Enumeral,
shall remain the sole property of Novartis (the “Novartis Background IP”). Enumeral shall acquire no right,
title or interest in the Novartis Background IP as a result of its performance of the Services. Enumeral is entitled to use, free
of charge, the Novartis Background IP solely in connection with this Agreement for the purpose of performing the Services.

 

		4.2	All intellectual property of Enumeral including without limitation Enumeral Technology which was
owned by or licensed to Enumeral prior to the Effective Date of this Agreement, shall remain the sole property of Enumeral
(the “Enumeral Background IP”).

 

		4.3	All inventions resulting from the performance of the Services, which are directed to or are an
improvement of Enumeral Technology and the Enumeral Background IP, and explicitly excluding Novartis Background IP shall be owned
by Enumeral (“Enumeral Improvements”), and Novartis hereby assigns to Enumeral all rights and title to such
inventions. For the avoidance of doubt, Enumeral Improvements do not include any Novartis Background IP, including without limitation,
Novartis Materials.

 

		4.4	All tangible and intangible materials, data, results, information, documents, reports, inventions
and discoveries (whether patentable or not), and know-how resulting from or arising out of the actual performance of the Services
(“Results”) and/or developed either by a Party alone or by both Parties in connection with this Agreement which
are specific for and inseparable from the Services , and any rights therein (but explicitly excluding Enumeral Technology, Enumeral
Background IP, and Enumeral Improvements), developed by Enumeral during the performance of the Services in accordance with this
Agreement (the “Novartis Results”) are hereby assigned to and shall be the exclusive property of Novartis (or
its designees) and may be used and/or transferred by Novartis and/or its Affiliates at their sole discretion with no further payment
or other obligation to Enumeral. In particular, Novartis shall be the owner of, and shall be entitled exclusively to use for any
purpose and commercially exploit at its sole discretion, all Novartis Results produced and/or developed by Enumeral without any
further obligation to, or the consent of Enumeral. Enumeral shall have no rights whatsoever in the Novartis Results. For the sake
of clarity, Novartis Results shall be considered Novartis Information (as defined in Section 3.1), and includes all Results directed
to and identifying * as described in Exhibit A.

 

    	Services Agreement Enumeral / Novartis	Page 3 of 12

    	 

    

 

Portions of this document have been redacted
pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under
the Securities Exchange Act of 1934, as amended. Redacted portions are indicated with the notation “*”.

 

		4.5	Enumeral agrees to, and to cause any employees to assign all right, title and interest in and to
any Novartis Results to Novartis or its designee, and to execute promptly all documents and take all such other action as may be
reasonably requested by Novartis in order to permit Novartis to obtain the benefit of its rights under this Agreement.

 

		4.6	Novartis shall be free to use and dispose of any Novartis Results and respective patent or other
intellectual property rights without any further compensation or obligations to Enumeral, its employees and/or its subcontractors.

 

		4.7	In the event of a third party asserting claims and/or filing suit against Enumeral due to an alleged
infringement of patents or other intellectual property rights in connection with the performance of the Services by Enumeral (an
“Action”), Enumeral shall promptly inform Novartis accordingly. Novartis and/or its Affiliates shall have the
exclusive right to defend and control the defense of any such Action, where such Action specifically relates to Novartis Background
Data and/or to Novartis Results (a “Novartis Action”), at its own costs, using counsel of its own choice, taking
into account the reasonable interest of Enumeral. The Parties will fully cooperate on the best course of action for defense against
any such Action; in particular, each Party shall have the right to propose defensive strategies and arguments and the other Party
agrees to take such strategies and arguments reasonably into consideration. Notwithstanding any other obligations of Enumeral under
this Agreement, Enumeral shall not enter into any amicable settlement or consent judgment with said third party without the prior
written consent of Novartis. Novartis agrees to indemnify and hold harmless Enumeral and its affiliates (including officers, directors,
employees and agents of Enumeral and/or its affiliates) from and against any and all such claims, suits and liabilities, including
costs and fees (including without limitation reasonable attorneys’’ fees) (collectively the "Intellectual Property
Claims") if related to such Novartis Action, except to the extent that such Intellectual Property Claims are based on
Enumeral's utilization of Enumeral Technology for performing the Services.

 

		4.8	In the event of a third party asserting claims and/or filing suit against Novartis due to a claim
that the Enumeral technology infringes patents or other intellectual property rights of a third person(an “IP Action”),
Novartis shall promptly inform Enumeral accordingly. Enumeral and/or its Affiliates shall have the exclusive right to defend and
control the defense of any such IP Action, where such IP Action solely relates to Enumeral Technology or Enumeral Improvement (a
“Enumeral Action”), at its own costs, using counsel of its own choice, taking into account the reasonable interest
of Novartis. The Parties will fully cooperate on the best course of action for defense against any such IP Action; in particular,
each Party shall have the right to propose defensive strategies and arguments and the other Party agrees to take such strategies
and arguments reasonably into consideration. Notwithstanding any other obligations of Novartis under this Agreement, Novartis shall
not enter into any amicable settlement or consent judgment with said third party without the prior written consent of Enumeral..

 

		5.	INDEMNIFICATION

 

		5.1	Enumeral agrees to indemnify, defend and hold Novartis (including all its officers, directors,
employees, contractors and agents) harmless from and against any and all third party claims, demands, causes of action, damages,
liabilities, losses, costs and expenses, including reasonable attorneys’ fees (collectively, the “Claims”)
related to Enumeral’s gross negligence or willful misconduct in performing of the Services in accordance with this Agreement,
except to the extent that such Claims were caused by the gross negligence of Novartis. For the avoidance of doubt Enumeral shall
only indemnify Novartis in an amount not to exceed the amount of consideration received by Enumeral in the performances of the
Services.

 

    	Services Agreement Enumeral / Novartis	Page 4 of 12

    	 

    

 

Portions of this document have been redacted
pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under
the Securities Exchange Act of 1934, as amended. Redacted portions are indicated with the notation “*”.

 

		5.2	Enumeral warrants that it has appropriate and adequate insurance to cover claims or damages for
which it shall be liable under the terms of this Agreement. Upon request of Novartis, Enumeral shall provide reasonable evidence
of its insurance.

 

		6.	TERM

 

		6.1	This Agreement shall become effective on the Effective Date and shall automatically terminate on
31st of March 2014 unless earlier terminated in accordance with Section 7.

 

		7.	TERMINATION

 

		7.1	Either Party may terminate this Agreement immediately at any time by written notice if the other
Party:

 

		(a)	is in breach of any of its obligations under this Agreement and fails or is unable to remedy such
breach within thirty (30) days of receipt of notice in writing specifying the breach.

 

		(b)	is or states that it is unable to pay its debts as they fall due, enters into any scheme of arrangement
or composition with, or assignment for the benefit of all or any class or creditors, is wound up or has a liquidator, provisional
liquidator, receiver and manager or statutory or other official manager appointed over all or any part of its property.

 

		7.2	Termination of this Agreement shall be without prejudice to any claim or right of action of either
Party against the other Party for any prior breach of this Agreement. The provisions of Section 3, Section 4, Section 5, Section
8 and Section 9 shall remain in force and effect notwithstanding the termination or expiration of this Agreement.

 

		8.	PUBLICATIONS

 

Neither Party
shall make any publication, lecture, manuscript, poster presentation or other disclosure or dissemination (oral or written) containing
Confidential Information or Results or referring to the Services, either during the term of this Agreement or after its termination
or expiration, without the prior written approval of or the other Party.

 

		9.	PUBLICITY

 

		9.1	Enumeral may disclose that Novartis has retained Enumeral for professional services in immunological
profiling without the prior written permission of Novartis. However, Enumeral may disclose that it has entered into this Agreement
to current and prospective shareholders, investors and lenders. For the sake of clarity, Enumeral may only disclose the terms of
this Agreement under confidentiality obligations at least as stringent as the confidentiality terms contained in this Agreement,
and only in connection with disclosure to and response to questions arising from prospective shareholders, investors and lenders
in Enumeral; said disclosure would not be aimed at publicity for the company.

 

		9.2	Neither Party will use, or authorize others to use, the name, symbols, or marks of the other Party
in any advertising or publicity material or make any form of representation or statement with regard to the Services which would
constitute an express or implied endorsement by the other Party of any commercial product or service without that other Party’s
prior written approval.

 

    	Services Agreement Enumeral / Novartis	Page 5 of 12

    	 

    

 

Portions of this document have been redacted
pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under
the Securities Exchange Act of 1934, as amended. Redacted portions are indicated with the notation “*”.

 

		10.	MISCELLANEOUS

 

		10.1	Assignment. This Agreement shall not be assignable in whole or in part without the prior
written consent of the other Party, except that Novartis shall be entitled to assign this Agreement or any rights and obligations
pertaining to this Agreement to any of its Affiliates or to a company taking over all or substantially all of its pharmaceutical
business. “Affiliate” as used in this Agreement shall have the meaning, with respect to a party, any Person that controls,
is controlled by, or is under common control with that party. For the purpose of this definition, “control” shall mean,
direct or indirect, ownership of fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors,
in the case of a corporation, or fifty percent (50%) or more of the equity interest in the case of any other type of legal entity,
status as a general partner in any partnership, or any other arrangement whereby the entity or person controls or has the right
to control the board of directors or equivalent governing body of a corporation or other entity, or the ability to cause the direction
of the management or policies of a corporation or other entity. In the case of entities organized under the laws of certain countries,
the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and in such case
such lower percentage shall be substituted in the preceding sentence, provided that such foreign investor has the power to direct
the management and policies of such entity. For the purpose of this Agreement the Genomics Institute of the Novartis Research Foundation,
San Diego, California, USA, and the Friedrich-Miescher Institute for Biomedical Research, Basel, Switzerland, shall also be considered
as Novartis’ Affiliates.

 

		10.2	Conflicting obligations. The Parties covenant and represent that each of them has full right
and authority to enter into this Agreement and to accept all the obligations under this Agreement, that they have no obligations
with any third party which is in conflict with their obligations under this Agreement, and that they will during the term of this
Agreement not enter into such obligations without the prior written consent of the other Party.

 

		10.3	Applicable law, Venue. This Agreement shall be construed in accordance with, and governed
by, the laws of New York, without regard to the conflicts of law provisions. Any dispute arising out of this Agreement shall be
submitted exclusively to the competent courts of New York, New York, without restricting any rights of appeal.

 

		10.4	Notices. Any notice required or authorized to be served hereunder shall be deemed to have
been properly served if delivered by hand, or sent by registered or certified mail, or sent by facsimile transmission confirmed
by registered or certified mail, to the party to be served at the address specified by such party for that purpose, or, if no such
address is specified, at the address given at the head of this Agreement. Notices sent by post shall be deemed to have been delivered
within seven days after the date of posting. Notices sent by facsimile shall be deemed to have been delivered within 24 hours of
the time of transmission.

 

		10.5	Entire Agreement. This Agreement represents the entire agreement and understanding between
the parties relating to the subject matter of this Agreement, and supersedes all documents or verbal consents or understandings
(if any) given or made between the parties prior to the date of this Agreement. None of the terms of this Agreement may be amended
or modified except by an instrument in writing signed by authorized representatives of the parties.

 

		10.6	Waivers. Neither party shall be deemed to have waived its rights under this Agreement unless
such waiver is in writing and signed by such party and such waiver by one party of a breach of any provision of this agreement
by the other party shall not be deemed to be a waiver of any subsequent or continuing breach of such provision or of the breach
of any other provision of this Agreement by that other party. Any delay or omission on the part of any party in the exercise of
its strict rights hereunder will not impair those rights nor will it constitute a renunciation or waiver of those rights. All rights,
remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative, and none of them shall be a
limitation of any other right, remedy, undertaking, obligation, or agreement of any of the parties.

 

    	Services Agreement Enumeral / Novartis	Page 6 of 12

    	 

    

 

Portions of this document have been redacted
pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under
the Securities Exchange Act of 1934, as amended. Redacted portions are indicated with the notation “*”.

 

		10.7	Force Majeure. Neither party shall be liable to the other party for any failure to perform
any obligation on its part hereunder to the extent that such failure is due to circumstances beyond its control which it could
not have avoided by the exercise of reasonable diligence. The affected party shall however notify the other party as soon as practicable
of the occurrence of any such circumstance, and the parties shall meet to consider what steps, if any, can be taken to overcome
any issues.

 

		10.8	Relationship. In performing the Services, Enumeral is acting as an independent contractor
and not as servant or agent of Novartis.

 

		10.9	Headings. Headings in this Agreement are included for ease of reference only and have no
legal effect.

 

		10.10	Annexes. All Annexes to this Agreement shall form an integral part of this Agreement. With
regard to any conflict between the terms of such Annexes and the terms of this Agreement, this Agreement shall govern.

 

		10.11	Third Party Code of Conduct. Novartis gives preference to third parties who share Novartis’
societal and environmental values, as set forth in the Novartis Third Party Code:

 

    	Services Agreement Enumeral / Novartis	Page 7 of 12

    	 

    

 

Portions of this document have been redacted
pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under
the Securities Exchange Act of 1934, as amended. Redacted portions are indicated with the notation “*”.

 

IN WITNESS WHEREOF, the Parties intending to
be bound have caused this Agreement to be executed by their duly authorized representatives.

 

	NOVARTIS PHARMA AG	 	ENUMERAL BIOMEDICAL CORP.
	 	 	 
	By:  	/s/ Hans-Peter Knopf	 	By:	/s/ Derek Brand
	 	 	 	 	 
	Name: 	Hans-Peter Knopf	 	Name: 	Derek Brand
	 	 	 	 	 
	Title:	Senior Biologics Expert Integrated	 	Title:	VP Business Development and Finance
	 	Biologics Profiling	 	 
	 	 	 
	NOVARTIS PHARMA AG	 	 
	 	 	 
	By:	/s/ Anette Karle	 	By:	/s/ John J. Rydzewski
	 	 	 	 	 
	Name:	Anette Karle	 	Name:	John J. Rydzewski
	 	 	 	 	 
	Title:	Fellow Law Head	 	Title:	Executive Chairman

 

List of Annexes:

 

Annex A:        Services

 

    	Services Agreement Enumeral / Novartis	Page 8 of 12

    	 

    

 

Portions of this document have been redacted
pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under
the Securities Exchange Act of 1934, as amended. Redacted portions are indicated with the notation “*”.

 

ANNEX A

 

Services

 

PART I: PROJECT INFORMATION

 

A.          Project Title: Enumeral technology
evaluation

 

B.          General Description

 

This program will utilize Enumeral’s
proprietary technology for the ex-vivo assessment of * from human samples *. In some cases, * therapeutics can lead to significant
adverse events such as *. * models of * can be poor predictors of the * response, leaving development groups with insufficient
(or in some cases inapplicable) data on which to base development decisions.

The ability to expose human cells ex-vivo,
subsequently followed by interrogation of *, at the level of single cells, allows enumeration of the responses and importantly
enables the resolution of the cellular subset originating the key response.

This program provides an example of how Enumeral’s
technology can be applied to the discovery and development process, and the potential to provide a more specific and reliable prediction
of human responses to the administration of * therapeutics.

 

C.          Services and Timeframe

 

Goal

 

Identify * responses to * therapeutics in samples
of human * using Enumeral’s technology. An assay will be developed which will allow identification of * profiles and expression
of cell surface markers at the level of single cells, and will be applied to patient samples using * supplied by Novartis, including
a positive control *), negative control (*), and * experimental groups, *. * will be provided by Novartis.

 

Experimental Plan

 

The experimental plan for this program will
proceed in two stages:

1. Assay design and testing

2. Assessment of * profiles under multiple
stimulation conditions

 

Assay Design and Testing

Enumeral’s scientists will develop an
assay that will measure * and cell surface markers suggested in discussions with Novartis scientists. Figure 1, below, shows a
proposed assay design which includes suggested * along with cell surface markers associated with *. Potential alterations to the
proposed assay design, such as indicators of * (such as * or surface markers) may be made after further discussion with Novartis.

The assay will be validated with spot assays
to ensure there is no appreciable bleed through between detection channels and there is a sufficient signal to noise ratio (SNR)
in each channel in order to execute the proposed experiments.

 

    	Services Agreement Enumeral / Novartis	Page 9 of 12

    	 

    

 

Portions of this document have been redacted
pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under
the Securities Exchange Act of 1934, as amended. Redacted portions are indicated with the notation “*”.

 

*

 

Assessment of * profiles from ex-vivo human
samples

* responses from ex-vivo human samples will
be assessed in samples of * under multiple incubation conditions, specifically * (Negative Control), * (Positive control), * (Experimental
conditions A and B, respectively). Blood samples will be sourced commercially (e.g. Research Blood Components) with * patients
being tested in all.

 

*

 

Enumeral Technology:

 

Enumeral’s technology has the ability
to comprehensively measure single-cell phenotypes with high throughput and high sensitivity by using addressable arrays of sub-nanoliter
wells for single-cell, analysis of secreted *, cell surface markers, and gene expression. Advantages include:

		·	Screening of single, unaltered cells.
The full repertoire of cellular expression – antibodies, * from any tissue is available for screening and analysis is unbiased.

		·	Measurement of many factors in parallel.
Antibody *, and genetic expression via in-well RT-PCR can be assayed from the same population of cells.

		·	Unmatched sensitivity. Because cells reside
in such a small volume *, very small amounts of * are needed for detection. Sensitivity can be greater than *.

		·	Ideal for small samples. Cells are loaded
directly onto the device without chemical or mechanical disturbance, preserving the full population of cells from a given sample
for analysis.

		·	Applicable to any cell/tissue types. Widely
demonstrated on blood samples, this technology can be applied to cells from any tissues (e.g. CSF, gut).

 

Process: (1-4) 50mm
x 50mm x 50mm (~85,000) wells are created on
a thin molded slab of polydimethylsiloxane (PDMS) the size of a standard microscope slide. Microwells are loaded with cells from
suspension and allowed to settle into wells. Array is placed in contact with a glass slide functionalized to bind proteins or
analytes secreted from the cells. This seals each microwell to define a collection of independent sub-nanoliter cultures confining
each cell and its secreted proteins. (5-8) Following protein capture, the cover slide is removed for analysis – microwells
are imaged via fluorescence microscope to verify well occupancy and identify cell surface markers. Cover slide is processed using
commercially-available “detector” antibodies to illuminate captured proteins. Cover slide is read in a microarray
reader, and “hits” are spatially correlated to cells in the associated microwells. Cells in microwells remain viable
and can be retrieved for expansion/further study.

 

    	Services Agreement Enumeral / Novartis	Page 10 of 12

    	 

    

 

Portions of this document have been redacted
pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under
the Securities Exchange Act of 1934, as amended. Redacted portions are indicated with the notation “*”.

 

 

D.          Novartis Materials

 

Novartis will provide *.

 

    	Services Agreement Enumeral / Novartis	Page 11 of 12

    	 

    

 

Portions of this document have been redacted
pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under
the Securities Exchange Act of 1934, as amended. Redacted portions are indicated with the notation “*”.

 

PART II: COSTS AND PAYMENT SCHEDULE

 

In consideration of the Project performed by
Enumeral, Novartis agrees to pay to Enumeral a fee in the amount of * according to the payment schedule outlined below plus VAT
if applicable.

 

Payment schedule:

 

	Services	 	Milestone	 	Deliverable 	 	
        Deliverable

        due date
	 	Payment
	 	 	 	 	 	 	 	 	* up front
	Assay design and testing	 	#1 Novartis approval of interim data report	 	Interim data report with results from *	 	*	 	*
	 	 	 	 	 	 	 	 	 
	Assessment of * profiles under multiple stimulation conditions	 	#2 Novartis approval of final report	 	Final Report detailing the results of the *	 	*	 	*
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	*

 

    	Services Agreement Enumeral / Novartis	Page 12 of 12Portions of this document have been redacted
pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under
the Securities Exchange Act of 1934, as amended. Redacted portions are indicated with the notation “*”.

 

 

Proposal Title: Microfluidic Chip *

Proposer: Fikst

Date: March 21, 2013

 

Fikst Contact:

*

Principal

45 Industrial Way

Woburn, MA 01801

 

Enumeral Biomedical:

Derek Brand

Director of Business Development

One Kendall Square, Bldg 400

Cambridge, MA 02139

 

Background

Enumeral has developed a system that uses a microwell array chip
(MC) for measuring protein secretion from cells. The MC is currently fabricated at Enumeral. The chips are made by *. The goal
of this program (the “Program” or “Project”) is to * by improving the production process including developing
improved tooling.

 

Key Design Considerations

 

		1.	*

		a.	The MC should be produced as * as possible with respect to the * that * to the *; this should result in * of all microwells
on the device. The tolerances are set forth in Exhibit A. The size of the MC to be fabricated is that of a standard glass microscope
slide (75x22mm)

		b.	During imaging the current * does linear * so it can correct for *. The specifications are set forth in Exhibit A

		2.	*

		a.	The current process has the slides *. The glass slides *.

		b.	 

		c.	During *, the *. Developing a controlled * method may *.

		d.	* is used to *. This process * making it *.

		3.	*

 

    	Proprietary and Confidential	Page 1 of 8

    	 

    

 

		a.	The current *. * provide * that may lead to * and resulting * of the *, leading to * collected thereafter. An improved * will
be proposed for approval.

		4.	*

		a.	The masters are currently * and *. An * for the masters is required.

		b.	The * are located only by the *. An improved alignment scheme for the * is required.

		5.	*

		a.	* a * under the wells is required for * and to stay within the *.

		6.	*

		a.	The chips should be *. The current process uses *.

		7.	*

		a.	MC’s are currently *. * and * will be considered during * to * MC *.

		8.	*

		a.	Fikst will develop the process and tooling appropriate for *.

		b.	Fikst will consider higher volume production when making design decisions and will, where reasonable, make decisions that are
appropriate for low and high volume production.

		c.	After the initiation of Phase 4 (Production, described below) Fikst will provide an estimate of the per-month production capacity
of the developed process along with design and process considerations for higher volume production to be considered in the future.

 

Assumptions

 

		1.	* will be supplied by Enumeral.

		2.	MC’s delivered by Fikst will *. Enumeral will * the MC’s as necessary before use.

		3.	Equipment and tooling that is necessary to the manufacture of the MCs will be paid for, after approval, by Enumeral and owned
by Enumeral. Equipment and tooling that improves Fikst’s capabilities and is not related to the manufacture of the MCs will
be paid for by Fikst and owned by Fikst. Some equipment may be shared expense with ownership to be determined by mutual agreement.

 

Statement of Work

 

Phase 1: Process Definition

a. Visit Enumeral

i. Fikst will visit Enumeral and
document the current * process in detail including inputs, method and output specifications.

ii. Fikst will develop design criteria
for the process and the tooling.

Deliverables: (i) Standard Operating Procedure
(SOP) for the current process

(ii) Design criteria for the * process and tooling.

Timeline: *

Condition for Proceeding to Phase 2: Approval
of Enumeral

 

Phase 2: Process and Tooling Design

		a.	Process Design

 

    	Proprietary and Confidential	Page 2 of 8

    	 

    

  

i. Fikst will develop an improved
SOP for * MC’s.

ii. Fikst will review options
for equipment that could be used to * the process (mixing equipment, inspection equipment, etc.).

b. Tooling Design

i. Fikst will brainstorm * to
the Enumeral tooling.

ii. Fikst will build proof-of-concept
prototypes of concepts as necessary.

iii. Fikst will build 3D CAD models
of the new tooling design.

c. Process and Tooling Design Review
with Enumeral

d. Tooling Build

i. Fikst will build, or have built
* of tooling to the new design.

Deliverables: (i) Improved
SOP (ii) CAD design of Tooling (iii) * of Tooling

Timeline: *

Condition for Proceeding to
Phase 3: Approval of Enumeral

 

Phase 3: Sampling

a. Process and Tooling Refinement

i. Fikst will set up a production line for Enumeral
MC *.

ii. Fikst will develop and debug the new process
and tooling.

b. Part Samples

i. Fikst will provide * MC production samples
for approval by Enumeral.

Deliverables: (i) * production MC Samples.

Timeline: *

Condition for Proceeding to Phase 4: Approval
of Enumeral

 

Phase 4: Production

a. Upon approval of production
MC Samples Fikst will produce chips for Enumeral that meet the mutually agreed upon quality.

b. Fikst will scale up capacity
to meet orders by Enumeral. Additional sets of tooling will be built as necessary.

Deliverables: (i) Production
MC’s as required

Timeline: On-going

 

Methodology:

 

Iteration: Our process will be highly iterative where we
will (i) brainstorm concepts, (ii) quickly build breadboard prototypes, (iii) test and review breadboards, and (iv) identify issues
with concepts. The identified issues will go back to brainstorming and we will repeat this process until concepts suitable for
detail design are developed.

 

Prototyping: In order to support our highly iterative approach
Fikst has a significant in-house prototyping capability including 3D Printing (FDM), CNC Machining, Laser Cutting and Silicone
Molding. By being able to test concepts quickly and inexpensively we are able to reduce development risk and quickly turn revolutionary
concepts into practical solutions.

 

    	Proprietary and Confidential	Page 3 of 8

    	 

    

  

Design Controls: Each client has a designated area in our
system for all electronic files. The primary engineer for the project will maintain the data, CAD and key project documentation
with revision control. Design Reviews will have PowerPoint slide decks which will document work since the last meeting including
design inputs and outputs as well as list next steps.

 

Project Budget

 

Non-recurring Engineering (NRE) for this project will be * due on
the following schedule:

 

		1.	Project Initiation: *

		2.	Completion of Phase 2: *

		3.	Sample Approval: *

 

Tooling cost will be in addition to the NRE and is expect to be
* per set. Between 3-6 sets of tooling are estimated to be sufficient for this process. Enumeral may stop this project at any time.
If the project is placed on hold a partial payment will be due based on completed work at Fikst standard rates; Fikst standard
rates are */hr for Principals; * for Engineers and * for Designers.

 

Expected MC Supply

 

Proposed MC Initial Cost will be * in quantities of * Lead Time
*.

 

Terms:

 

A.          Subject
to Paragraph D, Enumeral shall have the sole title, right and interest in and to all inventions, trade secrets, methodologies,
developments, data and results developed and/or generated by Fikst and/or any of its subcontractors (whether by itself or jointly
with others) in the performance of the Project, including but not limited to documents, drawings and electronic files and all intellectual
property rights such as know-how, patent, copy and design rights, clinical results and other information from the Project and shall
include the MCs, the Proposal, the development plan, any instruments and equipment such as the engineering prototypes and the pilot
production units to be delivered pursuant to the development plan (“Development Results”). Fikst irrevocably assigns
all, rights, title and interests in such Development Results, including but not limited to the Development Patents (as defined
in the following sentence) to Enumeral. “Development Patents” shall mean any and all patents, patent applications and
provisional patents pertaining to or resulting from Development Results, and all divisionals, continuations, continuations-in-part,
reissues, renewals, supplemental protection certificates, extensions or additions to any such patents and patent applications.
Fikst will cooperate with Enumeral, at Enumeral’s expense, in connection with filing one or more filings of patent applications
with any and all patent offices.

 

B.          To
the extent that any Background IP (as defined in the next sentence) is used in connection with or incorporated into any Development
Results and other deliverables hereunder, then Enumeral is hereby granted a nonexclusive fully paid up, royalty free, perpetual,
sublicensable and assignable license to such Background IP. “Background IP” shall mean all inventions, trade secrets,
methodologies, developments, data and results developed and/or generated by Fikst prior to the date hereof.

 

    	Proprietary and Confidential	Page 4 of 8

    	 

    

  

C.          All
employees working on the Project will execute agreements assigning all inventions conceived while working at Fikst to Fikst for
assignment to Enumeral and agreeing to keep confidential all confidential information of Enumeral including any Development Results,
in form and substance satisfactory to Enumeral. Copies of such agreements shall be made available to Enumeral upon its request.

 

D.          To
the extent that any Development Results (i) directly and solely relate to the general design and manufacturing processes created
by Fikst during the Project in performance of the services described hereunder, (ii) do not contain or are derived from confidential
information of Enumeral and (iii) do not require a license from Enumeral of any patents or patent applications (assuming such patent
applications were issued with the claims originally filed) licensed, owned or controlled by Enumeral (“General Manufacturing
Processes”), then Fikst shall own such General Manufacturing Processes (which shall also be considered Background IP for
purposes of Paragraph B above). Fikst hereby grants to Enumeral a royalty free, fully paid-up license to use such General Manufacturing
Processes to make, have made, sell, have sold, offer to sell, import products. The license granted to Enumeral in the foregoing
sentence shall be non-exclusive with respect to all application except that such license granted to Enumeral shall be exclusive
(even as to Fikst), transferable and sublicensable to the extent that it is used to manufacture an Enumeral *. An “Enumeral
*” means any *, containing * in the microarray where such wells are * or smaller in dimension or diameter and (ii) used directly
in the *, including but not limited to products *. Fikst agrees that it shall not use such * in an Enumeral *.

 

E.          Fikst
will perform the Project hereunder in compliance with federal, state and local laws and regulations. Fikst will not knowingly,
in the course of providing the services, use any tools, methods, materials, inventions or procedures that infringe any intellectual
property rights (including without limitation any patents) of any third party. Fikst represents that it will not commingle any
funding or grants from any other party including without limitation any governmental or quasi governmental entity with the funding
from Enumeral for the work being performed hereunder. The term “knowingly” as used above shall include where Fikst
should have reasonably known as well as actual knowledge.

 

F.          Fikst
shall execute the Project in a workmanlike and diligent manner consistent with the highest industry standards, in accordance with
the terms and subject to the conditions and limitations of this Agreement.

 

G.          Upon
reasonable prior notice to Fikst, Enumeral, at its own cost and expense, shall have the right to have a reasonable number of its
own employees on Fikst’s premises for the purpose of monitoring and working together with respect to the progress of the
Project.

 

    	Proprietary and Confidential	Page 5 of 8

    	 

    

  

H.          Fikst
shall not transfer or assign (whether through asset or stock sale, merger or consolidation) this Agreement or its rights and obligations
under this Agreement to any third party without Enumeral’s prior written consent. Fikst shall not subcontract any work to
be performed hereunder except with respect to vendor tooling, without the prior written consent of Enumeral, which will not be
unreasonably withheld, provided further that, if Enumeral requests, each such subcontractor executes and delivers to Fikst and
Enumeral an agreement in form and substance satisfactory to Enumeral assigning all of its rights, title and interest in any of
its work to Enumeral and agreeing to keep confidential all Enumeral information and the Development Results.

 

I.          This
Agreement shall be governed by and construed in accordance with the laws of Commonwealth of Massachusetts without regard to conflict
of laws principles.

 

J.          The
parties to this Agreement are independent contractors and not joint venturers or partners. Neither party shall be deemed to be
an agent of the other party as a result of any transaction under or related to this Agreement.

 

K.          No
provision of this agreement may be amended, modified or waived except by a mutually agreed executed written agreement.

 

    	Proprietary and Confidential	Page 6 of 8

    	 

    

  

Acceptance

 

As agreed by the Parties hereto:

 

Accepted: Enumeral Biomedical Corp.

By: Derek Brand

 

Signature: /s/ Derek Brand

 

Title: Director of Business Development

Date: 5/29/2013

 

Accepted: Fikst

By: Paul Sabin

 

Signature: /s/ Paul Sabin

 

Title: Principal

Date: 5/23/13

 

    	Proprietary and Confidential	Page 7 of 8

    	 

    

  

Exhibit A: Proposed device evaluation
procedure

 

		1.	* will be assessed using * to measure the * across each device provided by Fikst. * will be assayed to create *. The
                                                                measured * will be used to graphically reconstruct the *. Tolerable  * is less than * across the *, with a * of * from the *
                                                                to * of the *.

 

		2.	* will be assessed using * to measure the * throughout each device provided by Fikst. * will be measured in * and converted
to *. * resulting from * is less than * of the original *.

 

		3.	* will be assessed using * to measure the locations of individual * across each device provided by Fikst. Enumeral’s
existing * developed for the * contained in the * provided to Fikst will be used. All * must be visible in a * using the * to drive
to the desired *.

 

		4.	* in microengraving when loaded with * an antibody will be assayed for all devices supplied by Fikst that meet the above
criteria (1-3). Enumeral will perform microengraving to detect * antibodies from * of the supplied devices. This will occur by
covering a device * with an appropriately *. Device quality will be ascertained from the image quality and * in the resulting *.

 

    	Proprietary and Confidential	Page 8 of 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]